A retrospective study to evaluate the efficacy of Venetoclax when combined with hypomethylating agents (HMA) in blast phase myeloproliferative neoplasm
Latest Information Update: 11 Jan 2021
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Decitabine
- Indications Myeloproliferative disorders
- Focus Therapeutic Use
- 11 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology